ArticleScientific reports2025
A novel hybrid approach for multi stage kidney cancer diagnosis using RCC ProbNet.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Kidney renal cell carcinoma (RCC) is a highly invasive malignancy, where early-stage diagnosis can significantly reduce treatment complexity and mortality risk. This study aims to enhance diagnostic precision through a novel model, RCC-ProbNet, capable of identifying and classifying RCC across various stages. We introduce RCC-ProbNet, a hybrid deep learning model that incorporates an initial stage where features are extracted from medical imaging data, and a subsequent construction of a probabilistic feature model. This hybridized method could allow a more granular feature representation through incorporating a variety of features and enhance the model's ability to differentiate different RCC stages. The model is integrated with a Logistic Regression (LR) classifier for the final stage prediction. We validate performance using k-fold cross-validation. Overall, we obtain a notable diagnostic accuracy of 99.93% by RCC-ProbNet + LR, surpassing the current state-of-the-art techniques. Next, the model shows strong stability in different cross-validation folds. The comparative results also demonstrate that our model outperforms traditional and deep learning methods for RCC classification tasks consistently. The outstanding performance and the invulnerability of RCC-ProbNet + LR make it a powerful classifier for early RCC screening and staging in clinical practice. Its high performance indicates it has the potential to assist in timely and personalised treatments. Its future iterations may broaden the use toward real-time clinical decision support systems and consequently optimise patients' outcomes regarding renal oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.